SAN ANTONIO, April 28, 2026--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, ...
Please provide your email address to receive an email when new articles are posted on . Health information technology (HIT) use by patients with COPD was incrementally associated with pneumococcal ...
Pharmaceutical Technology on MSN
GSK’s Nucala secures NICE COPD endorsement
NICE now recommends Nucala for both severe asthma and COPD, expanding the drug’s clinical uptake across the UK’s public health service.
Two internationally renowned stem cell experts have found an abundance of abnormal stem cells in the lungs of patients who suffer from Chronic Obstructive Pulmonary Disease (COPD), a leading cause of ...
Researchers have found a novel, previously unreported pathogenic entity that is a fundamental link between chronic inflammation and tissue destruction in the lungs of patients with chronic obstructive ...
Study to explore the potential for proprietary flow cytometry+AI diagnostic tests targeting the asthma and COPD treatment market estimated at $92 billion1 bioAffinity Technologies, Inc. (Nasdaq: BIAF; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results